Why Regeneron Pharmaceuticals Dropped 11.3% in September

Why Regeneron Pharmaceuticals Dropped 11.3% in September

Despite sharing a series of positive news items with investors, shares of biotech-giant Regeneron Pharmaceuticals (NASDAQ: REGN) fell more than 11% in September, according to data from S&P Global Market Intelligence. 

Regeneron and its partner Sanofi (NYSE: SNY) made a number of announcements during the month that captured the market's attention.

Here's an overview of the key developments from the month:

Continue reading

Source: Fool.com